Immunomedics Inc (NASDAQ:IMMU) 2017 Q4 Institutional Investor Sentiment Steady

April 19, 2018 - By reb123z

Immunomedics, Inc. (NASDAQ:IMMU) Logo

Sentiment for Immunomedics Inc (NASDAQ:IMMU)

Immunomedics Inc (NASDAQ:IMMU) institutional sentiment decreased to 1.07 in Q4 2017. Its down -0.58, from 1.65 in 2017Q3. The ratio fall, as 76 institutional investors opened new or increased holdings, while 71 sold and reduced their holdings in Immunomedics Inc. The institutional investors in our partner’s database now possess: 117.18 million shares, up from 111.69 million shares in 2017Q3. Also, the number of institutional investors holding Immunomedics Inc in their top 10 holdings decreased from 8 to 7 for a decrease of 1. Sold All: 27 Reduced: 44 Increased: 47 New Position: 29.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $2.78 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

The stock decreased 0.71% or $0.12 during the last trading session, reaching $16.76. About 1.31M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 117.70% since April 19, 2017 and is uptrending. It has outperformed by 106.15% the S&P500.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on May, 9. They expect $-0.13 EPS, up 40.91 % or $0.09 from last year’s $-0.22 per share. After $-0.19 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -31.58 % EPS growth.

Acuta Capital Partners Llc holds 20.59% of its portfolio in Immunomedics, Inc. for 6.75 million shares. Venbio Select Advisor Llc owns 16.06 million shares or 16.83% of their US portfolio. Moreover, Ghost Tree Capital Llc has 5.83% invested in the company for 1.54 million shares. The New York-based Iguana Healthcare Management Llc has invested 4.74% in the stock. Opaleye Management Inc., a Massachusetts-based fund reported 898,800 shares.#img1#

Since January 1, 0001, it had 0 buys, and 1 insider sale for $2.05 million activity.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Ratings analysis reveals 100% of Immunomedics’s analysts are positive. Out of 2 Wall Street analysts rating Immunomedics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. IMMU was included in 2 notes of analysts from December 6, 2017. The rating was maintained by Cowen & Co on Wednesday, December 6 with “Buy”. The company was maintained on Wednesday, December 6 by Jefferies.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: